Health BETA digitalizes risk factors for cardiovascular disease, ischemic stroke and type 2 diabetes. It is a medical technology provider for medical practitioners and consumers to manage and prevent chronic diseases. Its vision is to harness the power of new insights drawn from the field of precision medicine to address the needs in prevention, detection and management of these chronic diseases.
Tan Kae Yuan
Before Health BETA, Tan was Managing Director of REKA, a venture he ran for 10 years since he co-founded in 2002. As the Managing Director, he set the vision for the company and defined the overall business strategy and was accountable for its business growth and profitability. Besides overseeing the day-to-day operations, his responsibilities included setting long-term goals and aligning human and financial resources against strategic business priorities. In 2011, he spun off a medical device business unit from REKA as a new entity called REKA Health. He filed patents and commercialized ECG3 and blood pressure monitor medical devices in REKA Health. He was the key person then for the product launch and for scaling up sales. He led a team to execute medical device regulatory compliance including CE, FDA and HSA; clinical validation and medical product marketing. He left REKA Health in 2015 and he is currently with Konica Minolta, where he is responsible for managing the P/L of a new business unit for South Asia region. The product portfolios managed under this business unit include robotics, video analytics, IoT sensors and chronic wound management. He has a bachelor’s degree in engineering.
Prof. Heng Chew Kiat
Professor Heng Chew Kiat has a PhD in Human Genetics and is an Associate Professor and Research Director with the Department of Paediatrics, Yong Loo Lin School of Medicine, NUS. In 1997, Prof. Heng received an exchange scholarship from the University of Pittsburgh for his molecular genetics training in the Department of Human Genetics. Subsequently, he was trained in genetic epidemiology at the Johns Hopkins University’s School of Public Health in 2000. Professor Heng’s research interests are in cardiovascular genomics. He has over 27 years of R&D experience. To-date, he has authored and published more than 100 scientific papers in peer-reviewed journals and filed 8 patents related to diagnostics tools. Prof Heng will serve as a scientific advisor for our data analysis and interpretation. His expertise in genomics will also be invaluable as we have plans to incorporate genetic testing for the Chronic Diseases as well.